Phospho-RACGAP1 (S387) Antibody

What is the structural and functional significance of RACGAP1 S387 phosphorylation?

RACGAP1 (Rac GTPase-activating protein 1) undergoes critical phosphorylation at serine 387 (S387) that fundamentally alters its biochemical function. This phosphorylation event transforms RACGAP1 from a Rac-specific GAP to a Rho-specific GAP, representing a molecular switch mechanism in GTPase regulation . Structurally, this modification occurs within a region critical for determining substrate specificity.

The methodological approach to studying this switch includes:

• Using phospho-mimetic mutants (S387D) to simulate constitutive phosphorylation

• Employing phospho-deficient mutants (S387A) to block phosphorylation

• Utilizing Phospho-RACGAP1 (S387) specific antibodies to track the phosphorylation state in various cellular contexts

• Performing in vitro GAP activity assays with purified wild-type and mutant proteins

During normal cell division, Aurora B kinase induces this phosphorylation at the midbody during cytokinesis, which is essential for proper completion of cell division . The phosphorylation-dependent alteration in substrate specificity allows RACGAP1 to regulate different GTPases at different stages of the cell cycle.

What are the recommended applications and dilutions for Phospho-RACGAP1 (S387) Antibody?

The Phospho-RACGAP1 (S387) Antibody has been validated for multiple applications with specific recommended dilutions for optimal results:

For experimental design considerations:

• Always include appropriate positive controls (e.g., v-Src-transformed NIH3T3 cells which show constitutive S387 phosphorylation)

• Include negative controls (e.g., phosphatase-treated samples)

• For Western blotting, consider using gradient gels (4-12%) to better resolve the ~71 kDa RACGAP1 protein

• When performing IF, co-staining with total RACGAP1 antibody can provide important information about the relative phosphorylation levels

The antibody has been validated with human, mouse, rat, and monkey samples, making it versatile for cross-species studies .

What are the proper storage and handling procedures for maintaining antibody activity?

Proper storage and handling of the Phospho-RACGAP1 (S387) Antibody is crucial for maintaining its specificity and sensitivity:

Storage Recommendations:

• Long-term storage: Store at -20°C or -80°C upon receipt

• Short-term/frequent use: Store at 4°C for up to one month

• The antibody is supplied in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

Handling Best Practices:

• Avoid repeated freeze-thaw cycles as this can degrade antibody performance

• Aliquot the antibody upon first thaw to minimize freeze-thaw cycles

• Allow the antibody to reach room temperature before opening the vial

• Centrifuge briefly before opening to collect liquid at the bottom of the tube

• When diluting, use fresh, sterile buffers appropriate for the application

Working Solution Preparation:

• For immunofluorescence: Dilute in PBS containing 1% BSA

• For Western blotting: Dilute in TBST containing 5% non-fat dry milk or BSA

• For IHC applications: Dilute in antibody diluent appropriate for the detection system

Implementing these storage and handling procedures will ensure consistent experimental results and maximize the lifespan of the antibody reagent.

How can Phospho-RACGAP1 (S387) Antibody be used to investigate cytokinesis mechanisms?

Phospho-RACGAP1 (S387) Antibody serves as a powerful tool for investigating the molecular mechanisms of cytokinesis, particularly the temporal and spatial regulation of Rho family GTPases. Research methodologies include:

Experimental Approaches:

• Time-lapse microscopy with phospho-specific immunostaining:

  • Fix cells at different stages of mitosis

  • Perform co-immunostaining with Phospho-RACGAP1 (S387) Antibody and markers for mitotic structures (e.g., α-tubulin, Aurora B)

  • Analyze the temporal appearance of S387 phosphorylation relative to mitotic progression

• Inhibitor studies to dissect phosphorylation pathways:

  • Treat cells with Aurora B kinase inhibitors to block phosphorylation

  • Use Phospho-RACGAP1 (S387) Antibody to confirm inhibition

  • Assess cytokinesis completion rates and phenotypes

• Biochemical isolation of midbody complexes:

  • Isolate midbody-enriched fractions from synchronized cell populations

  • Perform immunoprecipitation with Phospho-RACGAP1 (S387) Antibody

  • Identify interacting partners specific to the phosphorylated form

Based on published research, S387 phosphorylation by Aurora B kinase occurs specifically at the midbody during cytokinesis and is critical for completing cell division by converting RACGAP1 from a Rac-specific GAP to a Rho-specific GAP . This conversion allows precise temporal regulation of different GTPases during the final stages of cell division.

What is the relationship between RACGAP1 phosphorylation and cancer progression?

RACGAP1 phosphorylation status, particularly at S387, plays significant roles in cancer progression through multiple mechanisms:

Cancer-Specific Phosphorylation Patterns:

• In v-Src-transformed NIH3T3 cells, RACGAP1 is constitutively phosphorylated at S387 during interphase, unlike normal cells where this phosphorylation occurs primarily during cytokinesis

• The level of S387 phosphorylation correlates positively with soft agar colony-forming abilities in v-Src-transformed cells, indicating a role in anchorage-independent growth

• Expression of phospho-mimetic mutant RACGAP1-S387D enhances colony formation in v-Src-transformed NIH3T3 cells

Prostate Cancer Connection:

• RACGAP1 expression is markedly upregulated in prostate cancer patients with castration-resistant prostate cancer (CRPC) and enzalutamide resistance

• RACGAP1 forms a positive feedback loop with androgen receptor (AR) and its splice variant AR-V7, contributing to endocrine therapy resistance

• Nuclear RACGAP1 binds to the N-terminal domain (NTD) of both AR and AR-V7, preventing their degradation

Experimental Approaches for Cancer Research:

• Correlation studies in patient samples:

  • Use Phospho-RACGAP1 (S387) Antibody in tissue microarrays

  • Correlate phosphorylation levels with clinical parameters (Gleason score, tumor stage, therapy resistance)

• Xenograft models:

  • Establish xenografts with cells expressing wild-type RACGAP1 versus phospho-mimetic (S387D) or phospho-deficient (S387A) mutants

  • Monitor tumor growth and response to therapies

  • Use Phospho-RACGAP1 (S387) Antibody for immunohistochemical analysis

• Combination therapy studies:

  • In vivo experiments have shown that combining enzalutamide with RACGAP1 inhibition (using cholesterol-conjugated RIG-I siRNA drugs) potently inhibits xenograft tumor growth of prostate cancer

These findings highlight the potential of targeting RACGAP1 phosphorylation as a therapeutic strategy for cancer treatment, particularly in cases of therapy resistance.

How does RACGAP1 S387 phosphorylation status influence cell invasion and migration?

RACGAP1 phosphorylation plays a critical role in regulating cell invasion and migration through its effects on Rho family GTPases:

Molecular Mechanisms:

• RCP-driven α5β1 recycling promotes phosphorylation of RACGAP1, which suppresses Rac activity at the front of invasive pseudopods

• This local suppression of Rac promotes RhoA activity, which drives invasive migration

• In v-Src-transformed cells, a pathological positive feedback mechanism exists where Rac1 activation involves pS387-MgcRacGAP

Experimental Methodologies:

• 3D matrix invasion assays:

  • Culture cells in 3D matrices containing fibronectin

  • Analyze invasion while manipulating RACGAP1 phosphorylation status

  • Use Phospho-RACGAP1 (S387) Antibody to verify phosphorylation state

  • Quantify pseudopod formation and invasion depth

• Live-cell imaging of GTPase activity:

  • Employ FRET-based biosensors for Rac1 and RhoA

  • Simultaneously visualize RACGAP1 phosphorylation using fluorescently-tagged Phospho-RACGAP1 (S387) Antibody fragments

  • Track the spatiotemporal dynamics of GTPase activity in relation to RACGAP1 phosphorylation

• Protein complex analysis:

  • Perform immunoprecipitation with Phospho-RACGAP1 (S387) Antibody

  • Identify differential binding partners compared to non-phosphorylated RACGAP1

  • Focus on interactions with IQGAP1, which has been shown to form a complex with phosphorylated RACGAP1 at the tips of invasive pseudopods

Research has shown that phosphorylation of RACGAP1 promotes its recruitment to IQGAP1 at the tips of invasive pseudopods, where it locally suppresses Rac activity . This mechanism appears to be particularly important for cancer cell invasion and may represent a potential therapeutic target.

What techniques can be used to study RACGAP1 phosphorylation in different subcellular compartments?

Understanding the subcellular distribution of phosphorylated RACGAP1 provides crucial insights into its function in various cellular processes. Here are methodological approaches using Phospho-RACGAP1 (S387) Antibody:

Subcellular Fractionation and Analysis:

• Biochemical fractionation:

  • Separate nuclear, cytoplasmic, membrane, and cytoskeletal fractions

  • Perform Western blotting with Phospho-RACGAP1 (S387) Antibody on each fraction

  • Compare phosphorylation levels across different cellular compartments

  • Use appropriate compartment markers (e.g., GAPDH for cytoplasm, Lamin B1 for nucleus)

• High-resolution microscopy techniques:

  • Confocal microscopy with Phospho-RACGAP1 (S387) Antibody and compartment markers

  • Super-resolution techniques (STED, STORM, SIM) for more precise localization

  • Proximity ligation assay (PLA) to detect interactions with compartment-specific proteins

• Live-cell imaging approaches:

  • Use cell-permeable antibody fragments or nanobodies against phospho-S387

  • Employ FRET-based biosensors to monitor phosphorylation events in real-time

Research Findings:

• Nuclear RACGAP1 binds to the N-terminal domain of AR and AR-V7 in prostate cancer cells, preventing their degradation

• In v-Src-transformed NIH3T3 cells, RACGAP1 is prominently phosphorylated on S387 in the cytoplasm during interphase

• Phosphorylated RACGAP1 localizes to the midbody during cytokinesis, but redistributes to the invasive front in migrating cancer cells

This compartment-specific analysis is essential for understanding how RACGAP1 phosphorylation contributes to different cellular functions and how these functions might be dysregulated in disease states.

How can researchers distinguish between different phosphorylation sites on RACGAP1?

RACGAP1 undergoes phosphorylation at multiple sites, each with distinct functional consequences. Discriminating between these modifications requires specialized techniques:

Methodological Approaches:

• Multiplexed phospho-specific antibody detection:

  • Use Phospho-RACGAP1 (S387) Antibody in combination with antibodies against other phosphorylation sites (e.g., T249)

  • Employ different fluorophores for simultaneous detection in IF or different blotting membranes for WB

  • Compare relative phosphorylation patterns across different experimental conditions

• Mass spectrometry-based phosphoproteomics:

  • Immunoprecipitate RACGAP1 from cell lysates

  • Perform tryptic digestion followed by LC-MS/MS analysis

  • Quantify phosphopeptides corresponding to different phosphorylation sites

  • Validate findings using Phospho-RACGAP1 (S387) Antibody

• Phosphatase treatment controls:

  • Treat samples with lambda phosphatase before antibody detection

  • Compare with untreated samples to confirm phosphorylation specificity

  • Use phosphatase inhibitors to preserve phosphorylation status

Distinct Functional Roles:

• S387 phosphorylation converts RACGAP1 from a Rac-specific GAP to a Rho-specific GAP

• T249 phosphorylation promotes RACGAP1 recruitment to the front of invasive cells through association with IQGAP1

• Different kinases target specific sites: Aurora B phosphorylates S387 during cytokinesis, while other kinases may be responsible for phosphorylation in cancer contexts

Understanding the distinct patterns of RACGAP1 phosphorylation can provide insights into how this protein integrates multiple signaling pathways to regulate diverse cellular processes.

What are common challenges in detecting Phospho-RACGAP1 (S387) and how can they be addressed?

Researchers frequently encounter technical challenges when working with phospho-specific antibodies like Phospho-RACGAP1 (S387) Antibody. Here are methodological solutions to common issues:

Challenge: Weak or Absent Signal

• Potential causes: Low endogenous phosphorylation levels, phosphatase activity during sample preparation, antibody degradation

• Solutions:

  • Include phosphatase inhibitors (e.g., sodium orthovanadate, β-glycerophosphate) in lysis buffers

  • Consider enriching for phosphoproteins using TiO₂ or IMAC before Western blotting

  • Use stimuli known to induce S387 phosphorylation (e.g., Aurora B activators during M phase)

  • Optimize antibody concentration by testing a range of dilutions (1:200-1:2000 for WB)

  • Extend primary antibody incubation time (overnight at 4°C)

Challenge: High Background

• Potential causes: Non-specific binding, excessive antibody concentration, inadequate blocking

• Solutions:

  • Increase blocking time and concentration (5% BSA in TBST for 2 hours)

  • Add 0.1% Tween-20 to antibody dilution buffer

  • Pre-absorb antibody with cell lysate from RACGAP1 knockout cells

  • Use more stringent washing conditions (increase number and duration of washes)

Challenge: Multiple Bands in Western Blot

• Potential causes: Cross-reactivity with related proteins, degradation products, non-specific binding

• Solutions:

  • Validate specificity using phosphatase treatment controls

  • Add protease inhibitors to prevent degradation

  • Use RACGAP1 knockdown or knockout samples as negative controls

  • Consider using a gradient gel for better resolution of bands around the expected 71 kDa size

Challenge: Variable Results Between Experiments

• Potential causes: Inconsistent phosphorylation status, technical variations

• Solutions:

  • Standardize cell culture conditions and treatments

  • Ensure consistent sample handling and preparation

  • Include positive controls (e.g., v-Src-transformed cells)

  • Normalize phospho-signal to total RACGAP1 levels

These optimization strategies can significantly improve the quality and reproducibility of experiments using Phospho-RACGAP1 (S387) Antibody.

How can researchers validate the specificity of Phospho-RACGAP1 (S387) Antibody results?

Validating antibody specificity is crucial for ensuring reliable experimental results, particularly with phospho-specific antibodies. Here are rigorous validation methodologies:

Validation Strategies:

• Genetic approaches:

  • Use CRISPR/Cas9 to generate RACGAP1 knockout cells as negative controls

  • Create point mutation knock-in cells (S387A) that cannot be phosphorylated at this site

  • Perform rescue experiments with wild-type vs. S387A mutant RACGAP1

• Biochemical validation:

  • Treat lysates with lambda phosphatase to remove phosphorylation

  • Compare detection before and after treatment

  • Perform peptide competition assays using the phospho-peptide immunogen

• Physiological validation:

  • Compare antibody signal during different cell cycle stages (phosphorylation should increase during cytokinesis)

  • Test in v-Src-transformed cells where S387 phosphorylation is constitutively high

  • Use Aurora B kinase inhibitors to reduce phosphorylation and confirm antibody specificity

• Cross-validation with other methods:

  • Confirm phosphorylation status using mass spectrometry

  • Use alternative phospho-specific antibodies from different vendors

  • Employ genetic approaches like expressing tagged RACGAP1 constructs with S387A/D mutations

Example Validation Protocol:

• Split your samples into three portions

• Leave one untreated

• Treat second portion with lambda phosphatase

• Treat third portion with Aurora B kinase inhibitor (if working with dividing cells)

• Run all three on Western blot with Phospho-RACGAP1 (S387) Antibody

• A specific antibody should show signal reduction or elimination in treated samples

Implementing these validation strategies ensures that experimental findings truly reflect the phosphorylation status of RACGAP1 at S387 rather than artifacts or non-specific interactions.

What are the considerations for designing experiments to study the dynamics of RACGAP1 S387 phosphorylation?

Studying the dynamic regulation of RACGAP1 S387 phosphorylation requires careful experimental design. Here are methodological considerations:

Temporal Considerations:

• Cell cycle synchronization:

  • Use thymidine block, nocodazole treatment, or mitotic shake-off to enrich for specific cell cycle phases

  • Collect time-course samples to track phosphorylation changes during cell cycle progression

  • Aurora B-mediated phosphorylation of S387 peaks during cytokinesis

• Signaling dynamics:

  • Consider temporal resolution when sampling (seconds to minutes for fast changes, hours for slower processes)

  • Use rapid lysis techniques to preserve phosphorylation status

  • Employ phosphatase inhibitors throughout sample processing

Spatial Considerations:

• Subcellular localization:

  • Use subcellular fractionation combined with Western blotting

  • Employ high-resolution microscopy with co-localization markers

  • Consider that RACGAP1 localizes differently depending on cell cycle stage (midbody during cytokinesis)

• Micro-environmental effects:

  • Study phosphorylation in 2D versus 3D culture systems

  • Examine effects of cell-cell contact and matrix interactions

  • Consider analyzing leading edge versus trailing edge in migrating cells

Perturbation Strategies:

• Kinase/phosphatase manipulation:

  • Modulate Aurora B activity to alter S387 phosphorylation during cytokinesis

  • Use Rac1 inhibitors which can affect S387 phosphorylation in v-Src-transformed cells

  • Apply specific phosphatase inhibitors to prevent dephosphorylation

• Genetic approaches:

  • Express phospho-mimetic (S387D) or phospho-deficient (S387A) mutants

  • Use inducible expression systems for temporal control

  • Consider CRISPR-based approaches for endogenous protein modification

Analytical Methods:

• Quantitative approaches:

  • Use quantitative Western blotting with standard curves

  • Apply phospho-specific flow cytometry for single-cell analysis

  • Employ ELISA-based methods for high-throughput analysis